CureVac Financial Statements From 2010 to 2025

CVAC Stock  USD 3.82  0.05  1.29%   
CureVac NV financial statements provide useful quarterly and yearly information to potential CureVac NV investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on CureVac NV financial statements helps investors assess CureVac NV's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting CureVac NV's valuation are summarized below:
Gross Profit
-86.3 M
Market Capitalization
857 M
Enterprise Value Revenue
0.5657
Revenue
65.9 M
Earnings Share
0.49
We have found one hundred twenty available fundamental signals for CureVac NV, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to validate all of CureVac NV's prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. As of January 31, 2025, Market Cap is expected to decline to about 917.4 M. In addition to that, Enterprise Value is expected to decline to about 523.5 M

CureVac NV Total Revenue

55.62 Million

Check CureVac NV financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CureVac NV's main balance sheet or income statement drivers, such as Tax Provision of 80.9 K, Net Interest Income of 6.6 M or Interest Income of 15.6 M, as well as many indicators such as Price To Sales Ratio of 17.07, Dividend Yield of 0.0 or PTB Ratio of 1.77. CureVac financial statements analysis is a perfect complement when working with CureVac NV Valuation or Volatility modules.
  
Check out the analysis of CureVac NV Correlation against competitors.
For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.

CureVac NV Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets838.7 M906.5 M457.8 M
Slightly volatile
Other Current Liabilities70.9 M101.3 M41.5 M
Slightly volatile
Total Current Liabilities184.1 M214.3 M101.7 M
Slightly volatile
Other Liabilities198.2 M99.6 M107.2 M
Slightly volatile
Property Plant And Equipment Net171.9 M320.4 M112.1 M
Slightly volatile
Current Deferred Revenue56.8 M53.3 M29.2 M
Slightly volatile
Accounts Payable49.3 M53.3 M27.7 M
Slightly volatile
Cash565.5 M462.8 M267.7 M
Slightly volatile
Non Current Assets Total192.9 M356.3 M126.4 M
Slightly volatile
Non Currrent Assets Other1.2 MM613.8 K
Slightly volatile
Other Assets0.860.94.9 M
Slightly volatile
Cash And Short Term Investments575.6 M465.9 M291.6 M
Slightly volatile
Net Receivables23.6 M45.4 M15.8 M
Slightly volatile
Common Stock Total Equity26.1 M24.9 M9.1 M
Slightly volatile
Common Stock Shares Outstanding200 M254 M184.5 M
Slightly volatile
Short Term Investments2.3 M2.4 M23.4 M
Slightly volatile
Liabilities And Stockholders Equity838.7 M906.5 M457.8 M
Slightly volatile
Non Current Liabilities Total150.8 M76.4 M117.6 M
Slightly volatile
Inventory23.6 M28.5 M12.8 M
Slightly volatile
Other Current Assets17.5 M10.3 MM
Slightly volatile
Total Liabilities391.5 M312 M224.2 M
Slightly volatile
Deferred Long Term Liabilities258.2 K271.8 K649.4 K
Slightly volatile
Net Invested Capital459.1 M594.5 M238.4 M
Slightly volatile
Property Plant And Equipment Gross186 M347 M117 M
Slightly volatile
Total Current Assets645.8 M550.1 M331.4 M
Slightly volatile
Accumulated Other Comprehensive Income1.4 B2.4 B952.5 M
Slightly volatile
Capital Stock17.6 M30.9 M9.4 M
Slightly volatile
Non Current Liabilities Other16.2 K17.1 K557.2 K
Slightly volatile
Net Working Capital461.7 M335.8 M229.7 M
Slightly volatile
Short Term Debt3.5 M5.8 M1.9 M
Slightly volatile
Intangible Assets13.7 M18.3 M9.8 M
Slightly volatile
Common Stock17.6 M30.9 M9.4 M
Slightly volatile
Property Plant Equipment242 M230.5 M100 M
Slightly volatile
Short and Long Term Debt Total35.5 M37.6 M63 M
Slightly volatile
Long Term Debt52 M58.5 M63.8 M
Slightly volatile

CureVac NV Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income15.6 M14.9 M4.9 M
Slightly volatile
Depreciation And Amortization20.3 M26.9 M11.8 M
Slightly volatile
Interest Expense2.7 M2.9 MM
Slightly volatile
Selling General Administrative66 M87.4 M42.3 M
Slightly volatile
Selling And Marketing Expenses362.5 K381.6 K973.8 K
Slightly volatile
Total Revenue55.6 M61.8 M32.7 M
Slightly volatile
Other Operating Expenses279.2 M377.2 M179 M
Slightly volatile
Research Development218.7 M133.1 M117.4 M
Slightly volatile
Cost Of Revenue111.2 M143 M62.7 M
Slightly volatile
Total Operating Expenses170.6 M234.1 M117.4 M
Slightly volatile
Reconciled Depreciation14.5 M20.5 MM
Slightly volatile

CureVac NV Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow510 M570.2 M291.2 M
Slightly volatile
Depreciation15.5 M26.9 M9.8 M
Slightly volatile
Capital Expenditures64.3 M63.5 M37.3 M
Slightly volatile
End Period Cash Flow565.5 M462.8 M267.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio17.0717.96427
Slightly volatile
Days Sales Outstanding197308196
Very volatile
Capex To Depreciation3.262.123.8135
Pretty Stable
EV To Sales9.7410.25422
Slightly volatile
Inventory Turnover3.794.515.302
Slightly volatile
Days Of Inventory On Hand13283.7188.9951
Slightly volatile
Payables Turnover2.823.082.3104
Slightly volatile
Sales General And Administrative To Revenue1.561.631.5243
Pretty Stable
Research And Ddevelopement To Revenue3.52.483.1854
Very volatile
Capex To Revenue0.860.921.0873
Slightly volatile
Cash Per Share2.591.651.6505
Slightly volatile
Days Payables Outstanding214156189
Very volatile
Intangibles To Total Assets0.03420.04140.0411
Slightly volatile
Current Ratio2.562.312.8018
Pretty Stable
Receivables Turnover1.491.563.6601
Pretty Stable
Graham Number5.927.14.2349
Slightly volatile
Capex Per Share0.260.230.1936
Slightly volatile
Revenue Per Share0.220.24380.1697
Slightly volatile
Interest Debt Per Share0.20.180.1174
Slightly volatile
Debt To Assets0.0580.0610.0548
Pretty Stable
Operating Cycle329392285
Slightly volatile
Days Of Payables Outstanding214156189
Very volatile
Ebt Per Ebit1.11.090.9988
Slightly volatile
Long Term Debt To Capitalization2.342.632.8714
Slightly volatile
Total Debt To Capitalization0.08180.08610.1622
Pretty Stable
Quick Ratio2.452.192.6833
Pretty Stable
Net Income Per E B T0.80.90.9815
Slightly volatile
Cash Ratio1.981.941.5497
Slightly volatile
Days Of Inventory Outstanding13283.7188.9951
Slightly volatile
Days Of Sales Outstanding197308196
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.931.091.1603
Slightly volatile
Fixed Asset Turnover0.360.220.3025
Pretty Stable
Debt Ratio0.0580.0610.0548
Pretty Stable
Price Sales Ratio17.0717.96427
Slightly volatile
Asset Turnover0.09230.07840.0934
Slightly volatile

CureVac NV Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap917.4 M965.7 M6.5 B
Slightly volatile
Enterprise Value523.5 M551 M6.3 B
Slightly volatile

CureVac Fundamental Market Drivers

Forward Price Earnings5.2356
Cash And Short Term Investments405.1 M

CureVac Upcoming Events

23rd of April 2024
Upcoming Quarterly Report
View
4th of June 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
23rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About CureVac NV Financial Statements

CureVac NV stakeholders use historical fundamental indicators, such as CureVac NV's revenue or net income, to determine how well the company is positioned to perform in the future. Although CureVac NV investors may analyze each financial statement separately, they are all interrelated. For example, changes in CureVac NV's assets and liabilities are reflected in the revenues and expenses on CureVac NV's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in CureVac NV. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue53.3 M56.8 M
Total Revenue61.8 M55.6 M
Cost Of Revenue143 M111.2 M
Stock Based Compensation To Revenue 0.16  0.28 
Sales General And Administrative To Revenue 1.63  1.56 
Research And Ddevelopement To Revenue 2.48  3.50 
Capex To Revenue 0.92  0.86 
Revenue Per Share 0.24  0.22 
Ebit Per Revenue(4.59)(4.82)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether CureVac NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CureVac NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Curevac Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Curevac Nv Stock:
Check out the analysis of CureVac NV Correlation against competitors.
For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.49
Revenue Per Share
0.294
Quarterly Revenue Growth
0.905
Return On Assets
(0.25)
Return On Equity
(0.54)
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.